investigating the effect of Viola tablet on breast cancer-related fatigue

Phase 2

• Conditions: D05.9; Unspecified type of carcinoma in situ of breast; breast cancer.

• Registration Number: IRCT20220302054170N1
• Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 4 April 2022

Recruitment & Eligibility

• Status: Pending
• Sex: Female
• Target Recruitment: 20

Inclusion Criteria

Women aged 18 to 70 years old
Suffering from breast cancer
During radiotherapy
Hemoglobin at least 8 g / dl
Hematocrit at least 30%
SGOT level less than 3 times the upper limit of normal
Bilirubin less than 2mg / dl
Creatinine less than 2mg / dl
normal TSH

Exclusion Criteria

Heart disease with unstable conditions
Debilitating lung disease
History of asthma
History of allergies to Viola or any of the excipients in tablets
Uncontrolled pain
Severe infection
Serious accompanying disease

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Visual Analogue Fatigue Scale. Timepoint: In weeks 0 and 4. Method of measurement: Questionnaire and Visual scale.;Fatigue Severity Scale. Timepoint: In weeks 0 and 4. Method of measurement: Questionnaire and Visual scale.;The Cancer Fatigue Scale. Timepoint: In weeks 0 and 4. Method of measurement: Questionnaire and Visual scale.